Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Anders Toft; Thomas Urup; Ib Jarle Christensen; Signe Regner Michaelsen; Babloo Lukram; Kirsten Grunnet; Michael Kosteljanetz; Vibeke Andrée Larsen; Ulrik Lassen; Helle Broholm; Hans Skovgaard Poulsen

doi:10.1080/07357907.2018.1430818

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm, Hans Skovgaard Poulsen

Institut for Klinisk Medicin

3 Citationer (Scopus)

Abstract

Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

Originalsprog	Engelsk
Tidsskrift	Cancer Investigation
Vol/bind	36
Udgave nummer	2
Sider (fra-til)	165-174
Antal sider	10
ISSN	0735-7907
DOI	https://doi.org/10.1080/07357907.2018.1430818
Status	Udgivet - 7 feb. 2018

Adgang til dokumentet

10.1080/07357907.2018.1430818

Citationsformater

@article{92f6f95df13a4640bdbee76d18979951,

title = "Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan",

abstract = "Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bevacizumab/administration & dosage, Biomarkers, Tumor/analysis, Camptothecin/administration & dosage, Glioma/drug therapy, Humans, Irinotecan, Neoplasm Grading, Neoplasm Recurrence, Local/diagnosis, Prevalence, Survival Rate",

author = "Anders Toft and Thomas Urup and Christensen, {Ib Jarle} and Michaelsen, {Signe Regner} and Babloo Lukram and Kirsten Grunnet and Michael Kosteljanetz and Larsen, {Vibeke Andr{\'e}e} and Ulrik Lassen and Helle Broholm and Poulsen, {Hans Skovgaard}",

year = "2018",

month = feb,

day = "7",

doi = "10.1080/07357907.2018.1430818",

language = "English",

volume = "36",

pages = "165--174",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

AU - Toft, Anders

AU - Urup, Thomas

AU - Christensen, Ib Jarle

AU - Michaelsen, Signe Regner

AU - Lukram, Babloo

AU - Grunnet, Kirsten

AU - Kosteljanetz, Michael

AU - Larsen, Vibeke Andrée

AU - Lassen, Ulrik

AU - Broholm, Helle

AU - Poulsen, Hans Skovgaard

PY - 2018/2/7

Y1 - 2018/2/7

N2 - Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

AB - Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Bevacizumab/administration & dosage

KW - Biomarkers, Tumor/analysis

KW - Camptothecin/administration & dosage

KW - Glioma/drug therapy

KW - Humans

KW - Irinotecan

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local/diagnosis

KW - Prevalence

KW - Survival Rate

U2 - 10.1080/07357907.2018.1430818

DO - 10.1080/07357907.2018.1430818

M3 - Journal article

C2 - 29393706

SN - 0735-7907

VL - 36

SP - 165

EP - 174

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater